{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:41:30Z","timestamp":1791268890982,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bioorg.2019.103254","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T01:56:12Z","timestamp":1567734972000},"page":"103254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)\/PPAR\u03b4 agonists as potential anti-diabetic agents"],"prefix":"10.1016","volume":"92","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2019.103254_b0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2019.103254_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2019.103254_b0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2019.103254_b0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/092986708783330656","article-title":"Type 2 diabetes and oral antihyperglycemic drugs","volume":"15","author":"Avery","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"Stein","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bioorg.2019.103254_b0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrendo.2011.10","article-title":"Type 2 diabetes mellitus\u2014current therapies and the emergence of surgical options","volume":"7","author":"Lebovitz","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2019.103254_b0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2019.103254_b0040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/17460441.2014.941352","article-title":"Novel approaches to drug discovery for the treatment of type 2 diabetes","volume":"9","author":"Xu","year":"2014","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.bioorg.2019.103254_b0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2213-8587(15)00462-3","article-title":"Future glucose-lowering drugs for type 2 diabetes","volume":"4","author":"Bailey","year":"2016","journal-title":"Lancet Diabetes Endo."},{"key":"10.1016\/j.bioorg.2019.103254_b0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic \u03b2 cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2019.103254_b0055","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acs.chemrev.6b00056","article-title":"Complex pharmacology of free fatty acid receptors","volume":"117","author":"Milligan","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2019.103254_b0065","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1073\/pnas.1811066116","article-title":"Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40\/FFAR1","volume":"116","author":"Luckmann","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2019.103254_b0070","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.bmcl.2019.04.050","article-title":"Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs","volume":"29","author":"Pio","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103254_b0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/jpet.118.255885","article-title":"SCO-267, a GPR40 full agonist, improves glycemic and body weight control in rat models of diabetes and obesity","volume":"370","author":"Ueno","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2019.103254_b0080","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expert Opin. Inv. Drug"},{"key":"10.1016\/j.bioorg.2019.103254_b0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/med.21441","article-title":"Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges","volume":"38","author":"Li","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2019.103254_b0090","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2016.02.040","article-title":"Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"113","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0095","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bmc.2016.03.014","article-title":"Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"24","author":"Li","year":"2016","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0100","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1016\/j.bmc.2016.08.068","article-title":"Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry","volume":"24","author":"Li","year":"2016","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0105","doi-asserted-by":"crossref","first-page":"46356","DOI":"10.1039\/C6RA07356E","article-title":"Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2019.103254_b0110","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1016\/j.bmc.2015.09.010","article-title":"Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"23","author":"Li","year":"2015","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0115","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.bmc.2017.03.001","article-title":"Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker","volume":"25","author":"Yang","year":"2017","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejmech.2017.07.001","article-title":"Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"138","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bioorg.2017.12.012","article-title":"Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists","volume":"76","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bioorg.2018.01.039","article-title":"Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold","volume":"77","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0135","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bioorg.2018.06.039","article-title":"Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold","volume":"80","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0140","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.bmc.2018.07.050","article-title":"Nitric oxide donor-based FFA1 agonists: design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents","volume":"26","author":"Li","year":"2018","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0145","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPARdelta agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPAR gamma and PPAR delta","volume":"159","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0155","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4155\/fmc-2017-0113","article-title":"Quercetin\/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators","volume":"9","author":"Badolato","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0160","doi-asserted-by":"crossref","unstructured":"G. Carullo, M. Perri, F. Manetti, F. Aiello, M.C. Caroleo, E. Cione, Quercetin-3-oleoyl derivatives as new GPR40 agonists: molecular docking studies and functional evaluation, Bioorg. Med. Chem. Lett. (2019), doi: 10.1016\/j.bmcl.2019.05.018.","DOI":"10.1016\/j.bmcl.2019.05.018"},{"key":"10.1016\/j.bioorg.2019.103254_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-015-0149-2","article-title":"Promoter methylation status and expression of PPAR-gamma gene are associated with prognosis of acute-on-chronic hepatitis B liver failure","volume":"7","author":"Zhao","year":"2015","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.bioorg.2019.103254_b0170","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","volume":"1\u201318","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bioorg.2019.103254_b0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR gamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2019.103254_b0180","first-page":"7","article-title":"Clinical interest of PPARs ligands \u2013 particular benefit in type 2 diabetes and metabolic syndrome","volume":"30","author":"Verges","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.bioorg.2019.103254_b0185","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1073\/pnas.0510815103","article-title":"Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage","volume":"103","author":"Lee","year":"2006","journal-title":"P Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2019.103254_b0190","first-page":"313","article-title":"Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2019.103254_b0195","article-title":"Insights into the role of PPAR beta\/delta in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2019.103254_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPAR beta\/delta: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2019.103254_b0205","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2011.01.045","article-title":"PPAR beta\/delta activation induces enteroendocrine L cell GLP-1 production","volume":"140","author":"Daoudi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2019.103254_b0210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cellsig.2013.11.019","article-title":"Activation of PPAR beta\/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor","volume":"26","author":"Yang","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2019.103254_b0215","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cmet.2013.10.012","article-title":"Desnutrin\/ATGL activates PPAR delta to promote mitochondrial function for insulin secretion in islet beta cells","volume":"18","author":"Tang","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2019.103254_b0220","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/ol0474406","article-title":"Synthesis of [1, 2, 4] triazolo [4, 3-\u03b1] piperazines via highly reactive chloromethyloxadiazoles","volume":"7","author":"Balsells","year":"2005","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2019.103254_b0225","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1021\/jm960160e","article-title":"Synthesis, ligand binding, and quantitative structure-activity relationship study of 3\u03b2-(4'-substituted phenyl)-2\u03b2-heterocyclic tropanes: evidence for an electrostatic interaction at the 2\u03b2-position","volume":"39","author":"Kotian","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103254_b0230","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103254_b0235","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1476-5381.2012.01911.x","article-title":"The use of animal models in diabetes research","volume":"166","author":"King","year":"2012","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.bioorg.2019.103254_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.08.108","article-title":"Animal models for diabetes: understanding the pathogenesis and finding new treatments","volume":"99","author":"King","year":"2016","journal-title":"Biochem. Pharmacol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819309344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819309344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:56:23Z","timestamp":1758614183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819309344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":48,"alternative-id":["S0045206819309344"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103254","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)\/PPAR\u03b4 agonists as potential anti-diabetic agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103254"}}